Cepharanthine Inhibits Endometriosis via Apoptosis and DNA Damage

Study Background and Research Question

Endometriosis is a chronic gynecological disorder affecting approximately 10% of women of reproductive age, characterized by the presence of endometrial tissue outside the uterine cavity. It frequently causes severe pelvic pain, infertility, and a high rate of recurrence even after surgical or hormonal interventions. Current therapies, including hormone modulation and surgical lesion removal, are limited by side effects, incomplete efficacy, and substantial recurrence rates. There is an urgent need for novel, well-tolerated therapies capable of targeting the disease at a mechanistic level. Plant-derived agents have emerged as promising candidates for such interventions, with a focus on maximizing efficacy while minimizing adverse effects.

Cepharanthine, a biscoclaurine alkaloid extracted from Stephania cepharantha Hayata, has a track record of clinical application in leukopenia management and exhibits anti-inflammatory, antiviral, and anticancer activities. However, its direct impact on endometriosis had not been rigorously examined in advanced preclinical models until the recent study by Chen et al. (Clin. Exp. Obstet. Gynecol. 2026; 53(7): 48879), which investigated cepharanthine’s disease-modifying properties across both organoid and in vivo platforms.

Key Innovation from the Reference Study

The primary innovation of the reference study lies in its integrated experimental approach: the use of patient-derived endometrial organoids alongside murine in vivo models to evaluate cepharanthine’s mechanistic effects on endometriosis. This dual-model design enables high translational relevance by recapitulating disease heterogeneity and capturing both cellular and tissue-level responses. Notably, the authors extended their mechanistic investigation beyond cell viability assays to interrogate pathways of DNA damage, cell-cycle regulation, and apoptosis, establishing a comprehensive profile of cepharanthine’s action in endometrial pathology.

Methods and Experimental Design Insights

The study employed a combination of primary human cell cultures, organoid technology, and animal modeling. Patient-derived ectopic endometrial stromal cells were isolated from ovarian endometrioma samples, while organoids were developed from eutopic endometrial tissue of women with endometriosis. The research team evaluated cepharanthine’s effects on cell viability, proliferation, and apoptosis in both immortalized and primary cells, as well as in three-dimensional organoid cultures. In parallel, a peritoneal endometriosis mouse model was established using female BALB/c mice to assess in vivo efficacy.

• Cepharanthine was administered to cell cultures and to mice via intraperitoneal injection.
• The study analyzed cell-cycle distribution by flow cytometry, assessed DNA damage markers (γ-H2AX), and evaluated protein expression changes in cyclin D1 and RAD51.
• Apoptosis was quantified by measuring cytochrome C release, caspase activation (caspase-9, caspase-3), and the balance between proapoptotic Bax and antiapoptotic Bcl-2 expression.
• Lesion size, proliferation (Ki-67), and apoptosis rates in murine endometriosis lesions were measured after treatment.

This methodology allowed the team to trace cepharanthine’s impact from molecular events (DNA damage and apoptosis) to tissue-level outcomes (lesion suppression).

Core Findings and Why They Matter

The study found that cepharanthine significantly reduced the viability of both immortalized and patient-derived endometrial stromal cells, as well as eutopic endometrial organoids. Mechanistically, cepharanthine induced DNA damage, as evidenced by increased γ-H2AX and downregulation of RAD51, a key DNA repair protein. Cell-cycle analysis revealed G0/G1 arrest, accompanied by reduced cyclin D1 expression. Apoptosis induction was confirmed by elevated cytochrome C release, activation of caspase-9 and caspase-3, upregulation of Bax, and downregulation of Bcl-2.

In the murine model, intraperitoneal cepharanthine treatment led to marked inhibition of endometriotic lesion growth. Treated lesions displayed decreased proliferation (lower Ki-67) and a significant increase in apoptosis. These outcomes demonstrate that cepharanthine disrupts the proliferative/apoptosis-resistant phenotype characteristic of endometriotic tissue, directly addressing the core pathophysiology of the disease.

The findings are particularly relevant given the scarcity of well-tolerated, non-hormonal treatment options that preserve fertility and minimize long-term side effects. By targeting fundamental mechanisms of cell survival and death, cepharanthine emerges as a promising candidate for further translational research in endometriosis therapy.

Comparison with Existing Internal Articles

Several recent reviews and experimental reports have explored cepharanthine’s role as a biscoclaurine alkaloid in apoptosis research, immunomodulation in cancer, and disease modeling. For example, "Cepharanthine Suppresses Endometriosis via Apoptosis and DNA Damage" independently confirms the reference study’s mechanistic focus—highlighting apoptosis induction and DNA damage as the core drivers of lesion regression. Additionally, "Cepharanthine Applications: Protocols and Innovations in Disease Models" discusses the workflow flexibility of cepharanthine in organoid and in vivo studies, noting its reproducible effects in cell death assays and as an anticancer drug adjuvant. These perspectives are consistent with the referenced work, reinforcing the compound's utility in advanced disease modeling and in addressing chemotherapy side effect mitigation.

Other resources, such as "Cepharanthine: Benchmarks for Apoptosis and Immunomodulation", provide detailed protocol recommendations and discuss the molecule’s well-characterized IC50 (90 µM) profile, supporting standardized use in both apoptosis and immunomodulatory studies. Collectively, the internal literature converges on cepharanthine’s robust efficacy and mechanistic clarity across both cancer and endometriosis models.

Limitations and Transferability

While the referenced study provides compelling preclinical evidence, certain limitations must be acknowledged. First, the in vivo experiments were performed in murine models, which, despite recapitulating key aspects of human disease, may not fully capture the complexity of endometriosis in women. Second, while organoid platforms offer improved disease modeling over standard 2D cultures, their ability to mimic the in vivo microenvironment is not absolute. Long-term safety, optimal dosing strategies, and fertility preservation effects remain to be established in human trials.

Transferability to clinical settings will require careful consideration of pharmacokinetics, delivery routes, and potential interactions with existing hormonal or immunomodulatory therapies. Nevertheless, the convergence of evidence across multiple preclinical platforms, as well as corroboration from independent internal reports, provides a strong rationale for advancing cepharanthine to early clinical investigation for endometriosis.

Protocol Parameters

• In vitro cell treatment: Cepharanthine concentrations up to 90 µM were used to assess cell viability and apoptosis, consistent with its reported IC50 (product information).
• Organoid modeling: Eutopic endometrial organoids were treated with cepharanthine for 24–72 hours to evaluate growth inhibition and induction of apoptosis.
• In vivo administration: Intraperitoneal injection was used in murine endometriosis models, with dosing regimens aligned to published safety and efficacy profiles.
• Readout assays: Apoptosis was quantified by caspase-3 and caspase-9 activity, cytochrome C release, and TUNEL staining in tissue sections.
• DNA damage assessment: γ-H2AX immunostaining and RAD51 expression analysis were employed to monitor induction of DNA damage and repair inhibition.

Research Support Resources

Researchers seeking to replicate or extend these workflows can employ high-purity cepharanthine for in vitro, organoid, or in vivo assays. Cepharanthine (SKU N2771, APExBIO) is a biscoclaurine alkaloid with validated antiperoxidant and apoptosis-inducing properties, suitable for modeling disease processes such as endometriosis and for studying chemotherapy side effect mitigation. Product documentation details solubility, recommended storage, and quality control assays. For advanced protocol optimization, the APExBIO resource provides additional technical guidance for endometriosis and apoptosis research.